Small enough to fit into a life this full
Setting High Standards in Growth Hormone Therapy
Precise GH delivery helps maintain a normal routine
Prefilled, premeasured (single-dose) device helps ensure accurate dosing
Automatic internal mixing allows simple reconstitution
Full amount of drug is delivered for less waste—maximizing cost savings
1. Nahata M., Morosco R. Reconstitution and utilization of growth hormone (somatropin) in three drug delivery systems. J Pediatr Pharm Pract. 1998;3(3):166-169.
Portability and flexibility for a full life
Small size and room temperature storage* allow for easy portability
Packaged in a 7-day supply to simplify travel
10 dosage strengths (from 0.2 mg to 2.0 mg, in 0.2-mg increments) for flexible dosing
No refrigeration necessary*
*Genotropin MiniQuick can be stored at room temperature for up to 3 months.
Easy-to-teach GH delivery
A. Attach the needle
B. Twist
C. Inject
Footnote:
Health care providers should supervise the first injection and be able to answer patient questions on proper use of reconstitution and delivery devices for GENOTROPIN. Patients and parents should be instructed to visually inspect the solution for particulate matter and discoloration prior to administration.
Indication
GENOTROPIN Lyophilized Powder (somatropin [rDNA origin] for injection) is indicated for the long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone (GH). Other causes of short stature should be excluded. GENOTROPIN is also indicated for long-term replacement therapy in adults with growth hormone deficiency (GHD) of either childhood- or adult-onset etiology. GHD should be confirmed by an appropriate growth hormone stimulation test.
Special Considerations
Growth hormone should not be initiated to treat patients with acute critical illness due to complications of surgery, trauma, or respiratory failure; the safety of continuing treatment in patients who develop acute critical illness during treatment with GH for approved uses has not been established. Patients with diabetes mellitus or glucose intolerance should be monitored closely, and insulin dosage may need to be adjusted during treatment with GH. Careful monitoring is also necessary if GH is administered in combination with other drugs metabolized by the CP450 pathway. GH should be used during pregnancy only if clearly needed and with caution in nursing mothers.
Physicians should be aware of the following precautions: Intracranial hypertension has been reported in a small number of patients; a higher incidence of slipped capital femoral epiphyses (SCFE) has been reported in pediatric patients with endocrine disorders. In clinical trials with GENOTROPIN in adults with GHD, the majority of side effects were symptoms of fluid retention, including peripheral swelling/edema, arthralgia, pain and stiffness of the extremities, myalgia, paresthesia, and hypoesthesia. These events were reported early in therapy and tended to be transient/responsive to dosage reduction.
Dr DeBartolo uses sophisticated lab test to determine the exact dosage of bio-identical hormones and treat with bio-identical estrogen, progesterone, testosterone, melatonin, thyroid, and other bio-identical hormones.
Small enough to fit into a life this full
Setting High Standards in Growth Hormone Therapy
Precise GH delivery helps maintain a normal routine
Prefilled, premeasured (single-dose) device helps ensure accurate dosing
Automatic internal mixing allows simple reconstitution
Full amount of drug is delivered for less waste—maximizing cost savings
1. Nahata M., Morosco R. Reconstitution and utilization of growth hormone (somatropin) in three drug delivery systems. J Pediatr Pharm Pract. 1998;3(3):166-169.
Portability and flexibility for a full life
Small size and room temperature storage* allow for easy portability
Packaged in a 7-day supply to simplify travel
10 dosage strengths (from 0.2 mg to 2.0 mg, in 0.2-mg increments) for flexible dosing
No refrigeration necessary*
*Genotropin MiniQuick can be stored at room temperature for up to 3 months.
Easy-to-teach GH delivery
A. Attach the needle
B. Twist
C. Inject
Footnote:
Health care providers should supervise the first injection and be able to answer patient questions on proper use of reconstitution and delivery devices for GENOTROPIN. Patients and parents should be instructed to visually inspect the solution for particulate matter and discoloration prior to administration.
Indication
GENOTROPIN Lyophilized Powder (somatropin [rDNA origin] for injection) is indicated for the long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone (GH). Other causes of short stature should be excluded. GENOTROPIN is also indicated for long-term replacement therapy in adults with growth hormone deficiency (GHD) of either childhood- or adult-onset etiology. GHD should be confirmed by an appropriate growth hormone stimulation test.
Special Considerations
Growth hormone should not be initiated to treat patients with acute critical illness due to complications of surgery, trauma, or respiratory failure; the safety of continuing treatment in patients who develop acute critical illness during treatment with GH for approved uses has not been established. Patients with diabetes mellitus or glucose intolerance should be monitored closely, and insulin dosage may need to be adjusted during treatment with GH. Careful monitoring is also necessary if GH is administered in combination with other drugs metabolized by the CP450 pathway. GH should be used during pregnancy only if clearly needed and with caution in nursing mothers.
Physicians should be aware of the following precautions: Intracranial hypertension has been reported in a small number of patients; a higher incidence of slipped capital femoral epiphyses (SCFE) has been reported in pediatric patients with endocrine disorders. In clinical trials with GENOTROPIN in adults with GHD, the majority of side effects were symptoms of fluid retention, including peripheral swelling/edema, arthralgia, pain and stiffness of the extremities, myalgia, paresthesia, and hypoesthesia. These events were reported early in therapy and tended to be transient/responsive to dosage reduction.
Dr DeBartolo uses sophisticated lab test to determine the exact dosage of bio-identical hormones and treat with bio-identical estrogen, progesterone, testosterone, melatonin, thyroid, and other bio-identical hormones.